A Phase 3 trial of the antibody therapeutic Cyramza (ramucirumab) has failed to reach its primary endpoint of overall survival in patients with liver cancer. The trial was comparing Cyramza plus best supportive care to placebo plus best supportive care as a second-line therapy.
